| PARP抑制剂应用后的卵巢癌三级预防 |
| |
| 引用本文： | 臧荣余. PARP抑制剂应用后的卵巢癌三级预防[J]. 肿瘤防治研究, 2023, 50(2): 109-112. DOI: 10.3971/j.issn.1000-8578.2023.22.1192 |
| |
| 作者姓名： | 臧荣余 |
| |
| 作者单位： | 200032 上海,国家医学中心,复旦大学附属中山医院妇科肿瘤科,复旦大学附属中山医院卵巢癌临床中心 |
| |
| 基金项目： | 国家自然科学基金（82273388, 81972429）;上海市科委医学创新研究专项（22Y21900300） |
| |
| 摘 要： | The tertiary prevention approaches of ovarian cancer include whole-person care, training of the patients to cooperate with physicians in the periods of treatment and follow-up, training program of the qualified surgeons, and recognition of biological behavior changes of relapse after PARPi therapy. Surgery remains the cornerstone in the management of ovarian cancer, but the role of surgery after PARPi remains unknown. Recently, the US FDA withdrew the indication of three PARP inhibitors in the treatment of recurrent ovarian cancer with ≥3 lines of chemotherapy because of their ≥30% increased death risk. Thus, we should pay more attention to the biological recurrence and chemoresistance caused by PARP inhibitors and post-progression survival in ovarian cancer. © 2023, CHINA RESEARCH ON PREVENTION AND TREATMENT. All rights reserved.
|
| 关 键 词： | 卵巢癌 三级预防 PARP抑制剂 耐药 |
| 收稿时间： | 2022-10-12 |
Tertiary Prevention of Ovarian Cancer After PARP Inhibitor Therapy |
| |
| ZANG Rongyu. Tertiary Prevention of Ovarian Cancer After PARP Inhibitor Therapy[J]. Cancer Research on Prevention and Treatment, 2023, 50(2): 109-112. DOI: 10.3971/j.issn.1000-8578.2023.22.1192 |
| |
| Authors: | ZANG Rongyu |
| |
| Affiliation: | Department of Gynecologic Oncology, Ovarian Cancer Center, Zhongshan Hospital, Fudan University, National Medical Center, Shanghai 200032, China |
| |
| Abstract: | The tertiary prevention approaches of ovarian cancer include whole-person care, training of the patients to cooperate with physicians in the periods of treatment and follow-up, training program of the qualified surgeons, and recognition of biological behavior changes of relapse after PARPi therapy. Surgery remains the cornerstone in the management of ovarian cancer, but the role of surgery after PARPi remains unknown. Recently, the US FDA withdrew the indication of three PARP inhibitors in the treatment of recurrent ovarian cancer with ≥3 lines of chemotherapy because of their ≥30% increased death risk. Thus, we should pay more attention to the biological recurrence and chemoresistance caused by PARP inhibitors and post-progression survival in ovarian cancer. |
| |
| Keywords: | Ovarian Cancer Tertiary prevention PARP inhibitors Chemoresistance |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《肿瘤防治研究》浏览原始摘要信息 |
|
点击此处可从《肿瘤防治研究》下载全文 |
|
